Israeli Startup Hopes to Battle Alzheimer’s
The Fellowship | February 11, 2020
While the road ahead will be long, lab testing by Israeli researchers shows that an enzyme-inhibiting compound might slow down the progress of Alzheimer’s, reports the Times of Israel:
Israeli startup ProteKt Therapeutics is developing a drug to treat early stages of Alzheimer’s by targeting an enzyme that is believed to play a part in the development of the devastating neurodegenerative disease that causes memory loss and the inability to function.
The startup hopes that by inhibiting the enzyme, it will be able to bring about cognitive improvements in patients and slow the progress of the disease. It also hopes that the same treatment, when developed, could help with other neurodegenerative diseases such as ALS, Huntington and Parkinson’s.